Oncopeptides Overview

  • Founded
  • 2000
Founded
  • Status
  • Public
  • Employees
  • 160
Employees
  • Stock Symbol
  • ONCO
Stock Symbol
  • Share Price
  • $0.84
  • (As of Wednesday Closing)

Oncopeptides General Information

Description

Oncopeptides AB is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo), a peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment of hematological cancers and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Contact Information

Website
www.oncopeptides.se
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
STO
Primary Office
  • Luntmakargatan 46, 7th floor
  • 111 37 Stockholm
  • Sweden
+46 08-615 00 00

Oncopeptides Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncopeptides Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.84 $0.84 $0.40 - $14.04 $63M 75.3M 1.47M -$1.89

Oncopeptides Financials Summary

In Thousands,
USD 		TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (1,264) (6,332) 1,265,978 637,490
Revenue 13,671 13,775 0 0
EBITDA (132,851) (162,968) (171,021) (77,693)
Net Income (146,651) (166,551) (172,955) (78,312)
Total Assets 28,167 48,551 115,415 106,259
Total Debt 0 1,568 2,359 1,593
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oncopeptides Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncopeptides‘s full profile, request access.

Request a free trial

Oncopeptides Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Oncopeptides AB is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the
Pharmaceuticals
Stockholm, Sweden
160 As of 2021
00000
000000000 00000

00000000

strud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in
0000000000000
South San Francisco, CA
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oncopeptides Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
000000000 00000000 Venture Capital-Backed South San Francisco, CA 00 000.00 0000000000 0 000.00
You’re viewing 1 of 1 competitors. Get the full list »

Oncopeptides Patents

  • 80

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 7

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Oncopeptides Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020259142-A1 Novel formulations comprising melflufen Pending 17-Apr-2019 000000000
CA-3133886-A1 Novel formulations comprising melflufen Pending 17-Apr-2019 000000000
CA-3116198-A1 Compounds containing deuterium Pending 18-Oct-2018 00000000000
EP-3866931-A1 Compounds containing deuterium Pending 18-Oct-2018 00000000000
AU-2019362389-A1 Compounds containing deuterium Pending 18-Oct-2018 C07K5/06191
To view Oncopeptides’s complete patent history, request access »

Oncopeptides Executive Team (20)

Name Title Board Seat Contact Info
Jakob Lindberg MD Chief Scientific Officer
Anders Martin-Löf Chief Financial Officer & Deputy Chief Executive Officer
Annika Muskantor Interim Chief Financial Officer
Eva Nordström Chief Operating Officer
Klaas Bakker MD Chief Medical Officer & Executive Vice President
You’re viewing 5 of 20 executive team members. Get the full list »

Oncopeptides Board Members (12)

Name Representing Role Since
Brian Stuglik Self Board Member 000 0000
Cecilia Wennborg Self Board Member 000 0000
Jarl Jungnelius Ph.D Self Board Member 000 0000
Jennifer Jackson Ph.D Self Board Member 000 0000
Jonas Brambeck Ph.D Industrifonden Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Oncopeptides Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncopeptides Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oncopeptides‘s full profile, request access.

Request a free trial